PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.36%
Negative revenue growth while MRVL stands at 10.23%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.87%
Negative gross profit growth while MRVL is at 10.24%. Joel Greenblatt would examine cost competitiveness or demand decline.
-84.09%
Negative EBIT growth while MRVL is at 83.95%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-84.09%
Negative operating income growth while MRVL is at 83.95%. Joel Greenblatt would press for urgent turnaround measures.
-76.02%
Negative net income growth while MRVL stands at 97.45%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-72.73%
Negative EPS growth while MRVL is at 100.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-70.00%
Negative diluted EPS growth while MRVL is at 100.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.65%
Share count expansion well above MRVL's 1.20%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-0.59%
Reduced diluted shares while MRVL is at 1.31%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-146.99%
Negative OCF growth while MRVL is at 89.79%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-206.14%
Negative FCF growth while MRVL is at 122.76%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
292.53%
Similar 10Y revenue/share CAGR to MRVL's 278.95%. Walter Schloss might see both firms benefiting from the same long-term demand.
292.53%
5Y revenue/share CAGR similar to MRVL's 278.95%. Walter Schloss might see both companies benefiting from the same mid-term trends.
49.47%
3Y revenue/share CAGR under 50% of MRVL's 267.81%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-487.74%
Negative 10Y OCF/share CAGR while MRVL stands at 731.73%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-487.74%
Negative 5Y OCF/share CAGR while MRVL is at 731.73%. Joel Greenblatt would question the firm’s operational model or cost structure.
-142.40%
Negative 3Y OCF/share CAGR while MRVL stands at 453.94%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-48.71%
Negative 10Y net income/share CAGR while MRVL is at 1782.20%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-48.71%
Negative 5Y net income/share CAGR while MRVL is 1782.20%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-87.00%
Negative 3Y CAGR while MRVL is 123.12%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
791.18%
10Y equity/share CAGR 1.25-1.5x MRVL's 599.45%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
791.18%
5Y equity/share CAGR 1.25-1.5x MRVL's 599.45%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
77.06%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.01%
AR growth well above MRVL's 6.37%. Michael Burry fears inflated revenue or higher default risk in the near future.
13.71%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
1.56%
Asset growth at 50-75% of MRVL's 2.41%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
0.18%
Under 50% of MRVL's 1.90%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-39.85%
We’re deleveraging while MRVL stands at 281.29%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
9.86%
R&D growth drastically higher vs. MRVL's 1.21%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
7.77%
SG&A growth well above MRVL's 7.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.